Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients
IntroductionMicroRNAs (miRNAs), key regulators of cellular pathways, play crucial roles in the pathogenesis of various diseases, including Human Immunodeficiency Virus (HIV). This study aimed to evaluate the expression and diagnostic potential of in silico-identified miRNAs (miR-124-3p, miR-27a-3p,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565068/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313977371197440 |
|---|---|
| author | Ilker Inanç Balkan Ilker Inanç Balkan Ilker Inanç Balkan Andleeb Shahzadi Haktan Sönmez Burhaneddin Oktan Muhammad Ihtisham Umar Bilgül Mete Fehmi Tabak Günnur Deniz Umut Can Küçüksezer |
| author_facet | Ilker Inanç Balkan Ilker Inanç Balkan Ilker Inanç Balkan Andleeb Shahzadi Haktan Sönmez Burhaneddin Oktan Muhammad Ihtisham Umar Bilgül Mete Fehmi Tabak Günnur Deniz Umut Can Küçüksezer |
| author_sort | Ilker Inanç Balkan |
| collection | DOAJ |
| description | IntroductionMicroRNAs (miRNAs), key regulators of cellular pathways, play crucial roles in the pathogenesis of various diseases, including Human Immunodeficiency Virus (HIV). This study aimed to evaluate the expression and diagnostic potential of in silico-identified miRNAs (miR-124-3p, miR-27a-3p, miR-548ac-3p, miR-3163) before and during antiretroviral treatment (ART), together with their correlations with immunological markers (CD4 count, CD4/CD45 ratio) and virological parameters (HIV RNA load).MethodsBlood samples and clinical data of 16 patients were collected at 4 different time points; before the initiation of ART (baseline), 1st, 2nd and 6th months following HIV diagnosis. 16 healthy controls were enrolled to this study. RT-qPCR and ELISA techniques were used to analyze miRNA expression levels while immunological markers (CD4 count and ratio) were assessed by flow cytometry.ResultsmiR-27a-3p expression was significantly increased at 2nd and 6th months of ART (p<0.001). miR-548ac-3p was upregulated at 6th month compared to healthy individuals and ART-naive subjects (p<0.05). miR-124-3p expression was significantly elevated in ART-naive subjects in comparison with healthy controls (p<0.001). Conversely, miR-3163 was downregulated in ART-naive, 1-month, and 2-month ART groups (p<0.001), but returned to normal levels by 6 months. miR-548ac-3p and miR-3163 showed moderate-to-strong positive correlations with CD4 counts (R=0.46, R=0.67; p<0.001). ROC analysis identified miR-3163 as a promising prognostic marker, with an AUC of 0.8561, (95% CI: 0.756–0.9265).DiscussionOur findings highlight the potential of miR-3163 as a robust prognostic biomarker for monitoring HIV progression and optimizing ART strategies. Validation in larger cohorts is warranted to confirm its clinical utility. |
| format | Article |
| id | doaj-art-8722c4bc032f49eea88c41e3b9172e2c |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8722c4bc032f49eea88c41e3b9172e2c2025-08-20T03:52:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15650681565068Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patientsIlker Inanç Balkan0Ilker Inanç Balkan1Ilker Inanç Balkan2Andleeb Shahzadi3Haktan Sönmez4Burhaneddin Oktan5Muhammad Ihtisham Umar6Bilgül Mete7Fehmi Tabak8Günnur Deniz9Umut Can Küçüksezer10Department of Immunology, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TürkiyeInstitute of Graduate Studies in Health Sciences, İstanbul University, İstanbul, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Medical Pharmacology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Medical Pharmacology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Medical Pharmacology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Pharmacy, COMSATS University Islamabad, Lahore, PakistanDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, TürkiyeDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TürkiyeDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TürkiyeIntroductionMicroRNAs (miRNAs), key regulators of cellular pathways, play crucial roles in the pathogenesis of various diseases, including Human Immunodeficiency Virus (HIV). This study aimed to evaluate the expression and diagnostic potential of in silico-identified miRNAs (miR-124-3p, miR-27a-3p, miR-548ac-3p, miR-3163) before and during antiretroviral treatment (ART), together with their correlations with immunological markers (CD4 count, CD4/CD45 ratio) and virological parameters (HIV RNA load).MethodsBlood samples and clinical data of 16 patients were collected at 4 different time points; before the initiation of ART (baseline), 1st, 2nd and 6th months following HIV diagnosis. 16 healthy controls were enrolled to this study. RT-qPCR and ELISA techniques were used to analyze miRNA expression levels while immunological markers (CD4 count and ratio) were assessed by flow cytometry.ResultsmiR-27a-3p expression was significantly increased at 2nd and 6th months of ART (p<0.001). miR-548ac-3p was upregulated at 6th month compared to healthy individuals and ART-naive subjects (p<0.05). miR-124-3p expression was significantly elevated in ART-naive subjects in comparison with healthy controls (p<0.001). Conversely, miR-3163 was downregulated in ART-naive, 1-month, and 2-month ART groups (p<0.001), but returned to normal levels by 6 months. miR-548ac-3p and miR-3163 showed moderate-to-strong positive correlations with CD4 counts (R=0.46, R=0.67; p<0.001). ROC analysis identified miR-3163 as a promising prognostic marker, with an AUC of 0.8561, (95% CI: 0.756–0.9265).DiscussionOur findings highlight the potential of miR-3163 as a robust prognostic biomarker for monitoring HIV progression and optimizing ART strategies. Validation in larger cohorts is warranted to confirm its clinical utility.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565068/fullHuman Immunodeficiency Virus (HIV)Antiretroviral Therapy (ART)MicroRNAs (miRNAs)miR-3163 expressionprognostic biomarkersCD4 T-lymphocyte count |
| spellingShingle | Ilker Inanç Balkan Ilker Inanç Balkan Ilker Inanç Balkan Andleeb Shahzadi Haktan Sönmez Burhaneddin Oktan Muhammad Ihtisham Umar Bilgül Mete Fehmi Tabak Günnur Deniz Umut Can Küçüksezer Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients Frontiers in Immunology Human Immunodeficiency Virus (HIV) Antiretroviral Therapy (ART) MicroRNAs (miRNAs) miR-3163 expression prognostic biomarkers CD4 T-lymphocyte count |
| title | Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients |
| title_full | Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients |
| title_fullStr | Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients |
| title_full_unstemmed | Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients |
| title_short | Longitudinal analysis of hsa-miR-3163, hsa-miR-124-3p, hsa-miR-548c-3p, and hsa-miR-27a-3p as prognostic biomarkers in HIV-infected patients |
| title_sort | longitudinal analysis of hsa mir 3163 hsa mir 124 3p hsa mir 548c 3p and hsa mir 27a 3p as prognostic biomarkers in hiv infected patients |
| topic | Human Immunodeficiency Virus (HIV) Antiretroviral Therapy (ART) MicroRNAs (miRNAs) miR-3163 expression prognostic biomarkers CD4 T-lymphocyte count |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565068/full |
| work_keys_str_mv | AT ilkerinancbalkan longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT ilkerinancbalkan longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT ilkerinancbalkan longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT andleebshahzadi longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT haktansonmez longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT burhaneddinoktan longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT muhammadihtishamumar longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT bilgulmete longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT fehmitabak longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT gunnurdeniz longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients AT umutcankucuksezer longitudinalanalysisofhsamir3163hsamir1243phsamir548c3pandhsamir27a3pasprognosticbiomarkersinhivinfectedpatients |